Bristol-Myers Squibb Company and Tsinghua University (China), have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers.
The collaboration brings together Bristol-Myers Squibb and Tsinghua University’s respective scientific expertise and capabilities with a focus on validating new targets and generating early drug candidates for clinical development.
Under the collaboration, The Innovation Center for Immune Therapy of Tsinghua University will conduct research on projects and Bristol-Myers Squibb will have an option to exclusively license therapeutic agents discovered by Tsinghua University.
The collaboration is an expansion of an existing relationship between Bristol-Myers Squibb and Tsinghua University that began in 2012 which focused on autoimmune target discovery, structural biology research as well as the science of mapping the 3D protein structure of biological molecular targets.
Tsinghua University Innovation Center for Immune Therapy (ICIT), a joint entity of the Institutes for Immunology and Institute of Technology Transfer at Tsinghua University, was established in August 2016. ICIT aims to accelerate transformation of basic scientific discoveries into innovative medicines. ICIT thus serves as an “incubator” for translational research “from target to hit” by providing seed money as well as technical expertise. The successful applications are expected to have sound scientific basis and carefully crafted plan to develop first-in-class lead molecules for immune-related diseases. Tsinghua University is a major research university in Beijing, China and a member of the elite C9 League of Chinese universities.